NCT07075718

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 610 (estimated)
• Sponsor: Glaukos Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Detailed description

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Compared to Timolol Ophthalmic Solution 0.5% Administered Twice Daily in Subjects with Open-Angle Glaucoma or Ocular Hypertension

Conditions

• Glaucoma

Interventions

Type	Name	Description
DRUG	Gen 2 Travoprost Intracameral Implant	travoprost
DRUG	Timolol eye drops 0.5%	timolol 0.5%
PROCEDURE	Sham Procedure	sham implant administration
OTHER	Placebo eye drops	artificial tears

Timeline

• Start date: 2025-06-12
• Primary completion: 2028-03-01
• Completion: 2032-03-01
• First posted: 2025-07-20
• Last updated: 2026-03-02

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study